Search results for "Zoledronate"

showing 3 items of 3 documents

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

2010

The potent anti-tumour activities of gamma delta T cells have prompted the development of protocols in which gamma delta-agonists are administered to cancer patients. Encouraging results from small Phase I trials have fuelled efforts to characterize more clearly the application of this approach to unmet clinical needs such as metastatic carcinoma. To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a V gamma 9V delta 2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients. Treatment was well tolerated and promoted the effector maturation of V gamma 9V delta 2 T …

Translational Studiesmedicine.medical_treatmentLymphocyte ActivationZoledronic AcidMetastasisTNF-Related Apoptosis-Inducing LigandProstate cancerT-Lymphocyte SubsetsImmunology and AllergyMedicineDiphosphonatesRemission InductionEsterasesImidazolesReceptors Antigen T-Cell gamma-deltaMiddle AgedMetastatic breast cancerTreatment Outcomemedicine.anatomical_structureDisease ProgressionCytokinesFemaleImmunotherapyBreast diseaseChemokinesT cellImmunologyBreast NeoplasmsInterferon-gammaHemiterpenesOrganophosphorus CompoundsBreast cancerAdjuvants ImmunologicVgamma9Vdelta2 T cells Zoledronate interleukin-2advanced breast cancer patientsHumansLymphocyte CountAgedCell ProliferationSalvage Therapybusiness.industryLysineMucin-1CancerImmunotherapymedicine.diseaseTumor Necrosis Factor Receptor Superfamily Member 7ImmunologyInterleukin-2Leukocyte Common Antigensbusiness
researchProduct

Current advances in γδ T cell-based tumor immunotherapy

2017

γδ T cells are a minor population (~5%) of CD3 T cells in the peripheral blood, but abound in other anatomic sites such as the intestine or the skin. There are two major subsets of γδ T cells: those that express Vd1 gene, paired with different Vγ elements, abound in the intestine and the skin, and recognize the major histocompatibility complex (MHC) class I-related molecules such as MHC class I-related molecule A, MHC class I-related molecule B, and UL16-binding protein expressed on many stressed and tumor cells. Conversely, γδ T cells expressing the Vδ2 gene paired with the Vγ9 chain are the predominant (50-90%) γδ T cell population in the peripheral blood and recognize phosphoant…

0301 basic medicinelcsh:Immunologic diseases. AllergyAdoptive cell transferadoptive transferT cellImmunologyReviewBiologyMajor histocompatibility complexγδ T cells03 medical and health sciencesInterleukin 210302 clinical medicineAdoptive transfer; Immunoevasion; Immunotherapy; Zoledronate; γδ T cells; Immunology and Allergy; ImmunologyMHC class ImedicineCytotoxic T cellImmunology and AllergyAdoptive transfer Immunoevasion Immunotherapy Zoledronate γδ T cellsGamma delta T cellγδ T cellMHC restriction030104 developmental biologymedicine.anatomical_structureImmunologybiology.proteinimmunoevasionimmunotherapylcsh:RC581-607030215 immunologyZoledronate
researchProduct

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

2007

Abstract The increasing evidence that γδ T cells have potent antitumor activity suggests their value in immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this end, we initiated a phase I clinical trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the γδ T-cell agonist zoledronate, either alone or in combination with low-dose interleukin 2 (IL-2), to activate peripheral blood γδ cells. Nine patients were enlisted to each arm. Neither treatment showed appreciable toxicity. Most patients were treated with zoledronate + IL-2, but conversely only two treated with zoledronate displayed a significant long-te…

Interleukin 2MaleCancer ResearchNeoplasms Hormone-Dependentmedicine.medical_treatmentT cellT-LymphocytesAntineoplastic AgentsLymphocyte ActivationZoledronic AcidArticleMetastatic carcinomaProstate cancerAntigenMedicineHumansAgedAged 80 and overSalvage TherapyBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryRemission InductionImidazolesProstatic NeoplasmsReceptors Antigen T-Cell gamma-deltaImmunotherapyMiddle Agedmedicine.diseaseVγ9Vδ2 T cellsZoledronateIL-2Hormone-refractory prostate cancerImmunotherapyCytokinemedicine.anatomical_structureTreatment OutcomeOncologyImmunologyFeasibility StudiesInterleukin-2Tumor necrosis factor alphaDrug Therapy CombinationImmunotherapybusinessmedicine.drug
researchProduct